Latest news with #JenniferCaringal
Associated Press
3 hours ago
- Business
- Associated Press
INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that UroGen Pharma Ltd. (URGN) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
SAN DIEGO, June 09, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of UroGen Pharma Ltd. (NASDAQ: URGN) securities between July 27, 2023 and May 15, 2025, all dates inclusive (the 'Class Period'), have until July 28, 2025 to seek appointment as lead plaintiff of the UroGen class action lawsuit. Captioned Cockrell v. UroGen Pharma Ltd., 25-cv-06088 (D.N.J.), the UroGen class action lawsuit charges UroGen as well as certain of UroGen's top current and former executives with violations of the Securities Exchange Act of 1934. If you suffered substantial losses and wish to serve as lead plaintiff of the UroGen class action lawsuit, please provide your information here: You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at [email protected]. CASE ALLEGATIONS: UroGen engages in the development and commercialization of solutions for specialty cancers. According to the complaint, UroGen's lead pipeline product is UGN-102 (mitomycin), an intravesical solution intended to treat low-grade intermediate risk non-muscle invasive bladder cancer. The UroGen class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) UroGen's ENVISION clinical study for UGN-102 was not designed to demonstrate substantial evidence of effectiveness of UGN-102 because it lacked a concurrent control arm; (ii) as a result, UroGen would have difficulty demonstrating that the duration of response endpoint was attributable to UGN-102; (iii) UroGen failed to heed the U.S. Food and Drug Administration's ('FDA') warnings about the study design used to support a new drug application ('NDA') for UGN-102; and (iv) as a result, there was a substantial risk that the NDA for UGN-102 would not be approved. The UroGen class action lawsuit further alleges that on May 16, 2025, the FDA published a briefing document in advance of its Oncologic Drugs Advisory Committee meeting regarding UroGen's NDA for UGN-102, which stated that '[g]iven that ENVISION lacked a concurrent control arm, the primary endpoints of complete response (CR) and duration of response (DOR) are difficult to interpret,' and that the FDA had 'recommended a randomized trial design to the Applicant several times during their product's development due to concerns with interpreting efficacy results' but UroGen 'chose not to conduct a randomized trial with a design and endpoints that the FDA considered appropriate.' On this news, the price of UroGen stock fell nearly 26%, according to the complaint. Then, on May 21, 2025, the UroGen class action lawsuit further alleges that the Oncologic Drugs Advisory Committee voted against approving the UGN-102 NDA, finding that the overall benefit-risk of the investigation therapy UGN-102 is not favorable in patients with recurrent low-grade, intermediate-risk non-muscle invasive bladder cancer. On this news, the price of UroGen stock fell nearly 45%, according to the complaint. THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired UroGen securities during the Class Period to seek appointment as lead plaintiff in the UroGen class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the UroGen class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the UroGen class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the UroGen class action lawsuit. ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information: Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices. Contact: Robbins Geller Rudman & Dowd LLP J.C. Sanchez, Jennifer N. Caringal 655 W. Broadway, Suite 1900, San Diego, CA 92101 800-449-4900 [email protected]
Associated Press
4 hours ago
- Business
- Associated Press
INVESTOR DEADLINE NEXT WEEK: Ibotta, Inc. (IBTA) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
SAN DIEGO, June 09, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Ibotta, Inc. (NYSE: IBTA) publicly traded securities pursuant and/or traceable to Ibotta's registration statement and related prospectus issued in connection with Ibotta's initial public offering (the 'IPO') held on or around April 18, 2024, have until Monday, June 16, 2025 to seek appointment as lead plaintiff of the Ibotta class action lawsuit. Captioned Fortune v. Ibotta, Inc., No. 25-cv-01213 (D. Colo.), the Ibotta class action lawsuit charges Ibotta as well as certain of Ibotta's top executives and directors, as well as the underwriters of the IPO, with violations of the Securities Act of 1933. If you suffered substantial losses and wish to serve as lead plaintiff of the Ibotta class action lawsuit, please provide your information here: You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at [email protected]. CASE ALLEGATIONS: Ibotta purports to be a technology company that allows consumer packaged goods brands to deliver digital promotions to millions of consumers through its network called the Ibotta Performance Network. According to the complaint, in its IPO, Ibotta sold 2.5 million shares at $88.00 per share. The Ibotta class action lawsuit alleges that the IPO's offering documents were materially false and/or misleading and/or failed to disclose that: (i) Ibotta did not properly warn investors of the risks concerning Ibotta's contract with The Kroger Co.; (ii) Kroger's contract was at-will, and Ibotta failed to warn investors that a large client could cancel its contract with Ibotta without warning; and (iii) despite providing a detailed explanation of the terms of Ibotta's contract with Walmart Inc., there was not a single warning of the at-will nature of Kroger's contract. As of the close of trading on April 17, 2025, Ibotta securities have traded significantly lower than the IPO price of $88.00 per share, according to the complaint. THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Ibotta publicly traded securities pursuant and/or traceable to the registration statement and related prospectus issued in connection with the IPO to seek appointment as lead plaintiff in the Ibotta class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Ibotta class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Ibotta class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Ibotta class action lawsuit. ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information: Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices. Contact: Robbins Geller Rudman & Dowd LLP J.C. Sanchez, Jennifer N. Caringal 655 W. Broadway, Suite 1900, San Diego, CA 92101 800-449-4900 [email protected]
Associated Press
2 days ago
- Business
- Associated Press
INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Zenas BioPharma, Inc. (ZBIO) Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit
SAN DIEGO, June 06, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Zenas BioPharma, Inc. (NASDAQ: ZBIO) securities pursuant and/or traceable to Zenas BioPharma's registration statement issued in connection with Zenas BioPharma's initial public offering (the 'IPO') held on or around September 13, 2024, and were damaged thereby, have until June 16, 2025 to seek appointment as lead plaintiff of the Zenas BioPharma class action lawsuit. Captioned Buathongsri v. Zenas BioPharma, Inc., No. 25-cv-10988 (D. Mass.), the Zenas BioPharma class action lawsuit charges Zenas BioPharma as well as certain of Zenas BioPharma's top executives and directors, as well as the underwriters of the IPO, with violations of the Securities Act of 1933. If you suffered substantial losses and wish to serve as lead plaintiff of the Zenas BioPharma class action lawsuit, please provide your information here: You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at [email protected]. CASE ALLEGATIONS: Zenas BioPharma is a clinical-stage biopharmaceutical company that engages in the development and commercialization of transformative immunology-based therapies. According to the complaint, in its IPO, Zenas BioPharma sold over 13 million shares at $17.00 per share. The Zenas BioPharma class action lawsuit alleges that the IPO's offering documents were materially false and/or misleading and/or failed to disclose that Zenas BioPharma materially overstated the amount of time that it would be able to fund its operations using existing cash and expected net proceeds from the IPO. The Zenas BioPharma class action lawsuit further alleges that on November 12, 2024, Zenas BioPharma filed its quarterly report for the period ended September 30, 2024, disclosing that Zenas BioPharma could fund it operations for the following 12 months, not 24 months, as Zenas BioPharma had stated in the IPO's registration statement. As of the close of trading on April 15, 2025, the closing price of Zenas BioPharma stock was $8.72, 48.7% below the IPO price, according to the complaint. THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Zenas BioPharma securities pursuant and/or traceable to the registration statement issued in connection with the IPO to seek appointment as lead plaintiff in the Zenas BioPharma class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Zenas BioPharma class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Zenas BioPharma class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Zenas BioPharma class action lawsuit. ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information: Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices. Contact: Robbins Geller Rudman & Dowd LLP J.C. Sanchez, Jennifer N. Caringal 655 W. Broadway, Suite 1900, San Diego, CA 92101 800-449-4900 [email protected]
Associated Press
27-05-2025
- Business
- Associated Press
DNUT INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Krispy Kreme, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
SAN DIEGO--(BUSINESS WIRE)--May 27, 2025-- Robbins Geller Rudman & Dowd LLP announces that The Krispy Kreme class action lawsuit – captioned Cameron v. Krispy Kreme, Inc., No. 25-cv-00332 (W.D.N.C.) – seeks to represent purchasers or acquirers of Krispy Kreme, Inc. (NASDAQ: DNUT) securities and charges Krispy Kreme as well as certain of Krispy Kreme's top executives with violations of the Securities Exchange Act of 1934. If you suffered substantial losses and wish to serve as lead plaintiff of the Krispy Kreme class action lawsuit, please provide your information here: You can also contact attorneysJ.C. SanchezorJennifer N. Caringalof Robbins Geller by calling 800/449-4900 or via e-mail at[email protected]. CASE ALLEGATIONS: Krispy Kreme, together with its subsidiaries, produces doughnuts. On October 26, 2022, Krispy Kreme commenced a small-scale test to offer doughnuts at McDonald's Corporation restaurants in Louisville, Kentucky and the surrounding area and on March 26, 2024, Krispy Kreme and McDonald's announced they would expand their partnership nationwide beginning in the second half of 2024, the complaint alleges. The Krispy Kreme class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) demand for Krispy Kreme products declined materially at McDonald's locations after the initial marketing launch; (ii) demand at McDonald's locations was a driver of declining average sales per door per week; (iii) the partnership with McDonald's was not profitable; (iv) the foregoing posed a substantial risk to maintaining the partnership with McDonald's; and (v) as a result, Krispy Kreme would pause expansion into new McDonald's locations. The Krispy Kreme class action lawsuit further alleges that on May 8, 2025, Krispy Kreme released its first quarter 2025 financial results, reporting its '[n]et revenue was $375.2 million . . . a decline of 15.3%' and a '[n]et [l]oss [of] $33.4 million, compared to prior year net loss of $6.7 million.' Additionally, Krispy Kreme announced that it is 'reassessing [its] deployment schedule together with McDonald's' and 'withdrawing its prior full year outlook and not updating it' due in part to 'uncertainty around the McDonald's deployment schedule,' the complaint alleges. On this news, the price of Krispy Kreme shares fell by nearly 25%, the Krispy Kreme class action lawsuit alleges. THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Krispy Kreme securities during the Class Period to seek appointment as lead plaintiff in the Krispy Kreme class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Krispy Kreme class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Krispy Kreme class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Krispy Kreme class action lawsuit. ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information: Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices. View source version on CONTACT: Robbins Geller Rudman & Dowd LLP J.C. Sanchez, Jennifer N. Caringal 655 W. Broadway, Suite 1900, San Diego, CA 92101 800-449-4900 [email protected] KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA INDUSTRY KEYWORD: CLASS ACTION LAWSUIT PROFESSIONAL SERVICES LEGAL SOURCE: Robbins Geller Rudman & Dowd LLP Copyright Business Wire 2025. PUB: 05/27/2025 11:15 AM/DISC: 05/27/2025 11:16 AM
Associated Press
19-05-2025
- Business
- Associated Press
ELV INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Elevance Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
SAN DIEGO, May 19, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that the Elevance Health class action lawsuit – captioned Miller v. Elevance Health, Inc., No. 25-cv-00923 (S.D. Ind.) – seeks to represent purchasers of Elevance Health, Inc. (NYSE: ELV) common stock and charges Elevance Health as well as certain of Elevance Health's executives with violations of the Securities Exchange Act of 1934. If you suffered substantial losses and wish to serve as lead plaintiff of the Elevance Health class action lawsuit, please provide your information here: You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at [email protected]. Lead plaintiff motions for the Elevance Health class action lawsuit must be filed with the court no later than July 11, 2025. CASE ALLEGATIONS: Elevance Health operates as a health benefits company. Among other things, the cost of providing health benefits to members is driven by the level of care a patient requires, often referred to as 'acuity,' and the members' utilization of the health benefits, according to the complaint. The Elevance Health class action lawsuit alleges that defendants throughout the class period made false and/or misleading statements and/or failed to disclose that: (i) Medicaid redeterminations were causing the acuity and utilization of Elevance Health's Medicaid members to rise significantly, as the members being removed from Medicaid programs were, on average, healthier than those who remained eligible for the programs; and (ii) this shift was occurring to a degree that was not reflected in Elevance Health's rate negotiations with the states or in its financial guidance for 2024. The Elevance Health class action lawsuit further alleges that on July 17, 2024, Elevance Health revealed that it was now 'expecting second half utilization to increase in Medicaid' and that it was 'seeing signs of increased utilization across the broader Medicaid population, including in outpatient home health, radiology, durable medical equipment as well as some elective procedures.' On this news, the price of Elevance Health stock fell nearly 6%, according to the complaint. Then, on October 17, 2024, the Elevance Health class action lawsuit further alleges that Elevance Health announced its financial results for the third quarter of 2024, revealing that Elevance Health had missed consensus earnings per share ('EPS') expectations for the quarter by $1.33, or 13.7%, 'due to elevated medical costs in [its] Medicaid business.' Elevance Health further revealed that it was lowering EPS guidance for 2024 from $37.20 to $33.00, or 11.3%, as it expected these Medicaid issues to continue, according to the complaint. The Elevance Health class action lawsuit alleges that on this news, the price of Elevance Health stock fell nearly 11%. THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Elevance Health common stock during the class period to seek appointment as lead plaintiff in the Elevance Health class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Elevance Health class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Elevance Health class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Elevance Health class action lawsuit. ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information: Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices. Contact: Robbins Geller Rudman & Dowd LLP J.C. Sanchez, Jennifer N. Caringal 655 W. Broadway, Suite 1900, San Diego, CA 92101 800-449-4900 [email protected]
